We assessed the pulmonary hemodynamic response to VEGFR2 inhibition using SU5416 (SU) with or without chronic hypoxia (CH) Lewis rats showed only a minimal response. All SD TT rats survived up to 13 weeks post SU/CH, whereas SD HT rats exhibited mortality after SU and SU/CH (35% and 50%, respectively) at 8 weeks.
RESULTS:

Effects of SU5416 on Systemic Hemodynamics and RV Remodeling
The response to SU treatment alone in the SD background was critically dependent on the specific colony from which the rats were obtained. At 7-8 weeks after SU injection, SD rats obtained from the Charles River colony exhibited marked increases in pulmonary arterial pressure and RV remodeling in response to SU alone (Figure 1: P<0.0001 vs. vehicle control), and therefore are referred to as "SDHyper-responsive Type" (SD HT ) rats. In contrast SD rats obtained from Harlan Labs showed no response to SU alone, which is typical for this background and are therefore are referred to as "SD-Typical Type" (SD TT ) rats. Of note, SD HT rats exhibited a bimodal response to SU alone (Supplement Figure S1A) ; a clear increase in RVSP observed in 13 of the 18 rats studied (72%), whereas there was little or no response in the remaining 5 SD HT animals. A similar bimodal trend was seen for RV remodeling as well (Supplement Figure 1B) . The combination of SU and CH did not produce any further increase in RVSP or RV hypertrophy in SD HT rats compared to SU alone ( Figure 1A and B), but did increase the consistency of the response for hemodynamic changes and RV remodeling (Supplemental Figure S1A and B). In contrast, SD TT and Fischer rats only developed severe PAH in response to SU together with CH ( Figures 1A and B) , and Lewis rats exhibited only modest PAH in response to SU/CH.
Occlusive lesions in the severe PAH rat model
Histological analysis of H&E stained lung sections from SD HT rats at 7-8 weeks after SU alone showed evidence of complex pulmonary arteriopathy, including occlusive plexiform-like lesions ( . In contrast, no occlusive lesions were seen in Lewis rats in the SU/CH group ( Figure 2E ). Similarly, the increase pulmonary arterial wall thickness was similar in SD HT rats exposed to SU alone and SU/CH (Supplement Figure S4A and B), while arterial remodeling in SD TT rats, was seen only in response to SU and CH. Moreover, the degree of wall thickening was similar in all backgrounds exposed to SU/CH, with the exception of Lewis rats (Supplement Figure S4C and D).
SD HRC rats exhibit increased susceptibility to SU5416-induced apoptosis
Caspase-3 activation was assessed at 1 week after treatment with SU5416 alone in lungs of SD HT and SD TT rats. Increased cleaved caspase-3 immunostaining was seen in lung sections from SD HT rats, which was associated with arteriolar endothelium as seen in adjacent sections stained with an endothelial marker, vWF (Supplemental Figure S3A ). Increased cleaved caspase-3 in lung lysates from SD HT rats was confirmed by immunoblotting (Supplemental Figure S3B and C) compared with SD TT .
Mortality after SU5416 treatment
Mortality at 8 weeks after SU injection was markedly different in the four different strains rats. SD HT rats treated with SU exhibited a significant mortality without or with CH (31% and 50%, respectively; p<0.05 ( Figure 3A and 4B)). In contrast, there was no mortality in SD TT and Lewis rats treated with SU or SU/CH. Mortality was the highest in Fischer rats exposed to SU/CH (77%; p<0.01).
The relationship between RV dysfunction and mortality in the rat model of severe PH Serial echocardiography was performed at regular intervals in the SU/CH model and RV adaptation was assessed by measuring RV relative to LV diameter in diastole. Figure 6A shows representative 2D echocardiographic images of from SD TT and Fischer rats under control conditions and in the SU/CH Strain differences in SU model of severe PAH | P a g e C o n f i d e n t i a l 9 model of severe PAH. Overall, there was a strong trend towards a greater increase in RVID-d/LVID-d
in Fischer compared to SD TT rats (p=0.06) in the severe PAH model, regardless of whether or not rats survived to the end-study at 8 weeks ( Figure 4D ). However, RV diameter during the final week of life was markedly increased in the non-surviving (NS) Fischer rats compared to surviving Fischer (p<0.01)
or SD TT rats (p<0.005), consistent with a strain-specific failure of RV adaptation in response to severe PAH in these animals.
Strain-dependent differences in recovery of severe PAH
Since SD TT rats showed no mortality at 8 weeks despite exhibiting severe PAH, a separate cohort was followed for more than 13 weeks after SU injection with or without CH. As before, the severe PAH phenotype was seen in animals treated with both SU and CH, and still no mortality was evident even at 13 weeks. Interestingly, not only was there no further increase in RVSP and RV hypertrophy, but RVSP and RV/LV+S at 13 weeks were significantly lower than at 8 weeks, which was also associated with a reduction in the number of occluded vessels at 13 weeks compared to 8 weeks post SU/CH ( Figure 5A ), consistent with possible resolution of occlusive arterial remodeling at late time points. As well, there was a direct correlation between RVSP and the number of occlusive lesions in these animals (Supplement Figure S2 ). In order to confirm an improvement in the severe PAH phenotype at later time points in this background, serial echocardiography was performed at 0, 3, 4, 8 and 13 weeks in both the the SD TT and the SD HT substrains in the SU/CH model ( Figure 5B ). In SD TT rats, the maximal decrease in PAAT was seen at 3 weeks of CH. There was a substantial initial recovery in PAAT (~30%) on the first week after return to normoxia ( Figure 5C ), and further improvement was seen from 8 to 13 weeks, yielding a total hemodynamic recovery of almost 75%. In contrast, SD HT rats showed no significant
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DISCUSSION:
We evaluated the response to SU5416 in the presence and absence of CH in different rat strains that have been used widely in experimental PH studies (5, (21) (22) (23) to better understand the importance of genetic background on the development of a severe PAH phenotype. We now report that even minor differences in background strain have a remarkable influence on both the severity and nature of the phenotype in the SU/CH model of severe PAH.
The development of a model of severe PAH that better reflects the pathological features of the human disease, in particular the development complex intimal and plexiform-like lesions (11) , has been an importance advance. Tuder and Voelkel were the first to report that inhibition of VEGFR2 using a receptor tyrosine kinase inhibitor, SU5416, accentuated the hemodynamic response to CH in SD rats and resulted in the appearance of intimal and complex arteriolar lesions (13). This was associated with a marked increase in endothelial cell (EC) apoptosis, and the effects of SU on both hemodynamics and vascular remodeling could be abrogated by nonspecific caspase inhibition, confirming a causal role of apoptosis in the severe PAH phenotype. This led to the concept that EC apoptosis triggered the emergence of apoptosis-resistant, hyperproliferative vascular cells that contributed to the formation of complex and occlusive pulmonary arteriolar lesions in PAH (24). Abe et al later demonstrated that severe PAH in SD rats in response to SU/CH was associated with excellent long-term survival over more than 13 weeks. While hemodynamic abnormalities were evident by 4 weeks, complex arteriopathy was not observed before 8 weeks after receiving the SU compound in this study (5) , prompting the authors to suggest that these lesions were a consequence rather than a cause of the hemodynamic abnormalities. Nonetheless, in the present study we found a direct correlation between RVSP and the number of occlusive lesions in SD rats (On line supplement, Figure S1 ), which is suggestive of a causal
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link between these lesions and the hemodynamic abnormalities of PAH. Moreover, we have previously reported the appearance of complex arterial lesions as early as 3 weeks in the severe PAH model (25), a time point at which the increased pulmonary pressures are first observed.
While no single model can recapitulate all features of the human disease, the SU/CH rat model has now been widely adopted as the most relevant for the study of basic mechanisms and novel treatment approaches in PAH. However, less is known about the response to SU/CH in background strains of rats other than SD. It is not uncommon for variable phenotypes to be found in different background strains.
Indeed, previous studies have reported marked differences in systemic arterial remodeling in various rat background strains after balloon injury (26) and in the severity of ischemic stroke even between rats of the same strain (SD)from different suppliers (27). As well, the Voelkel group has previously reported that athymic nude rats showed increased susceptibility to SU, developing severe PAH even without exposure to CH (16) . However, this trait was attributed to a disordered immune response due to loss of T-regulatory cell activity.
We first studied two different colonies of SD rats; one from Charles River laboratories, Canada and another Harlan Laboratories, USA. "Hyper-responder Type" SD (SD HT ) rats from the Canadian Charles
River colony developed severe PAH, including the development of occlusive arteriolar lesions, after even a single injection of the SU in the absence of CH. In contrast, the SD "Typical-Type" (SD TT ) rats from Harlan showed no response to SU alone and required both SU and CH to exhibit a PAH phenotype, as has previously been reported. Interestingly, the response of SD HT rats to SU alone was clearly biphasic with ~75% of animals exhibiting a severe PAH phenotype, while the rest showed no response. This "all or none" pattern of response suggests that susceptibility to SU could relate to a genetic trait that confers responsiveness to SU alone. Indeed, we found that SD HT rats from the Canadian Charles River colony exhibit a marked increase in lung activated caspase-3 in response to SU5416 alone by both immunostaining and Western blotting, whereas there was no detectable increase caspase activity in the SD TT rats. Therefore, these animals are uniquely susceptible to inhibition of VEGFR2, and do not require a second hit, such as hypoxia, for EC injury and apoptosis to be manifested after treatment with SU5416. This is consistent with the possibility of mutations in the SD HT substrain in genes that may modify the activity of pathways involved in EC growth and survival. In contrast, Lewis rats were the least responsive, showing no significant hemodynamic abnormalities and only minimal RV remodelling in response to SU/CH and no evidence complex vascular lesions. Such exquisite sensitivity to variation in strain and even colony supports the importance genetic modifiers in determining both the susceptibility to SU and the severity of the PAH phenotype in response to SU and CH. It should be noted that SD represents an outbred strain, and this no doubt contributes to some of the variability in response to SU between different substrains and colonies.
Interestingly, SD TT rats obtained from Harlan Laboratories tolerated severe PAH following treatment with SU and CH remarkably well, with no mortality for up to 13 weeks. In contrast, Fischer rats exhibited a high mortality in the SU/CH model of severe PAH compared with SD rats, despite comparable severity of hemodynamic abnormalities, which was consistent with a previous report (17) .
We hypothesized that this marked difference in survival may be due to strain-specific differences in the ability of the RV to adapt to chronic increases in afterload. Indeed, on serial echocardiographic assessments RV dilatation was only seen in the Fischer rats that later showed mortality. This finding suggests that a defect in RV adaptation to the increase in afterload in severe PAH contributed to poor survival in the Fischer background strain. RV dysfunction is well recognized as the major determinant
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for poor outcome and death in PAH patients (29, 30) and, therefore, this model provides a unique opportunity to explore both the mechanisms underlying RV failure in severe PH and develop strategies aimed at improving RV adaptation in severe PH.
The SU/CH model has been considered to be a model of irreversible PAH (12) . However, using continuous hemodynamic monitoring (21), it was recently reported that SU/CH induced PAH was partially reversible in Charles River SD rats obtained from a German supplier, with a substantial reduction in RVSP occurring mainly after the return to normoxic conditions, despite progressive increases in occlusive intimal arterial remodeling. In our study, we also found a significant improvement in RVSP and RV remodeling from 8 to 13 weeks post SU/CH in SD TT rats, which, in contrast to the previous report, was associated with a reduction in the number of occlusive arterial lesions. Again, this is consistent with a tight relationship between hemodynamic abnormalities and arterial remodeling in this model, both in the development and resolution of severe PAH. As well, serial echocardiographic assessment confirmed improvement pulmonary hemodynamics in the same animals over this period in the SU/CH model. In contrast, SD HT rats from the Canadian colony failed to show any improvement in PAAT on return to normoxia or over the next 5 weeks under conditions of normoxia. It is intriguing that such marked differences in reversibility were observed in our study compared to the previous report of de Raaf et al. despite using the same outbred strain of rats from the same supplier (i.e. Charles River) (21). These findings may once again point to the substrain-dependent differences in the severe PAH phenotype such that colonies from the same supplier may vary based on geographic location (Canada vs. Germany).
| P a g e C o n f i d e n t i a l 15 We have shown that differences in background strain have a profound influence of the severity and nature of the PAH phenotype in response to SU. In particular, we have identified a specific colony of SD rats exhibiting hyper-responsiveness to SU alone. In addition to the obvious importance of this unique colony for the identification of potential genetic modifiers, the use of the SD HT background will allow a wider access to a severe PAH model even in labs that do not have access to chronic hypoxia chambers. In contrast, "typical-type" Sprague Dawley rats show excellent survival in the SU/CH model and are well suited to study novel therapies of established PAH using a "treatment" protocol. As well, the high mortality seen in Fischer rats likely reflects a strain-specific defect in RV adaptation in response to the increased hemodynamic load, and this background is uniquely well suited to study mechanisms of RV remodeling, whereas Lewis rats were unresponsive to SU/CH and are not a suitable strain for this model of PAH. Thus, the present findings will be highly relevant for the selection of the appropriate background strain for future experimental studies using the SU/CH model, and also provide novel insights into the mechanisms underlying the development and adaptation to severe PAH in different rat strains. 
Transthoracic Echocardiographic Evaluation
Non-invasive assessment of RV structure and function parameters was performed by echocardiography (Vevo 2100, VisualSonics, Toronto, Ontario) (19, 20). The transducer was aligned to show pulmonary artery in the parasternal view and pulmonary outflow was recorded using pulsed-wave Doppler mode. Pulmonary artery acceleration time was measured using recorded pulmonary artery (PA) waveform from the time of onset of systolic flow to peak outflow velocity. PA pressure was estimated by the measurement of pulmonary artery acceleration time (PAAT). Using M-mode echo, RV wall thickness was measured as the distance between the epicardium and the endocardium of the right ventricular wall. RV failure was evaluated by the ratio of end-diastolic RV to LV internal diameter (RVID-d/LVID-d) in Mmode.
Western Blotting
Immediately after excision, the right lobe of the lung was snap frozen in liquid nitrogen and stored at -80 o C until lysis. Protein lysate was made by homogenizing frozen lung portions (~25 mg) in RIPA buffer (Millipore) with protease inhibitors (Roche) using the Qiagen TissueLyser II system (Qiagen, Toronto, Canada) at 30 Hz for 5 minutes. Protein lysate was quantified using the BCA (bicinchoninic acid assay) method. To prepare samples for SDS-PAGE, 4X LDS sample buffer (Life Technologies, Burlington, ON, Canada) and 10X antioxidant (Life Technologies, Burlington, ON, Canada) was added to 50 ug of lung protein lysate and heated to 70 o C for 10 minutes. Afterwards, samples were underwent electrophoresis on NuPAGE 4-12% Bis-Tris gels in MES Buffer (Life Technologies, Burlington, ON, Canada). Gels were transferred onto nitrocellulose membranes using the iBlot apparatus (Life Technologies). Membranes were blocked for 1 hour at room temperature using 5% milk in TBS-T. Afterwards, membranes were incubated overnight with primary antibody to cleaved caspase-3 (Cell Signaling Technologies, Whitby, ON, Canada) at a 1:1000 dilution and detected with goat anti-rabbit IR800 secondary antibodies (LiCor, Lincoln, NE, USA). Following detection of cleaved caspase-3, β-actin (Sigma-Aldrich, Oakville, ON, Canada) was probed (1:20,000 dilution) and used as a loading control.
Immunofluorescence staining for cleaved caspase-3
Paraformaldehyde fixed paraffin-embedded tissue sections were deparaffinized as previously described (Methods). Following antigen retrieval (Vector Labs, Burlington, ON, Canada), tissue specimens were blocked and incubated overnight at 4 o C with 1:100 dilution of cleaved caspase-3 antibody (Asp 175, Cell Signaling Technologies, Whitby, ON, Canada) or 1:200 von Willebrand factor (vWF, Dako, Burlington, ON, Canada). Antigens were detected using the VectaFluor Excel Amplified Dylight 594 anti-rabbit (Vector Labs, Burlington, ON, Canada) according to manufacturers protocol. Slides were mounted using VECTASHIELD Hardset mounting medium (Vector labs, Burlington, ON, Canada) and coverslipped prior to imaging by fluorescence microscopy (20X magnification).
Vessel wall morphology analysis
Hematoxylin and eosin stained slides were used for vessel wall analysis. Scanned images of each slide (10X magnification) were analyzed using ImageJ. External diameter (ED) was measured as the minimum diameter of the vessel including adventitia. Wall thickness (WT1 and WT2) was measured, as the distance between the vessel exterior to the lumen, at opposing ends. Wall 
